Evidence map›Paper›PMID 30200948›Full record

ArticleBMC complementary and alternative medicine2018

Weipixiao attenuate early angiogenesis in rats with gastric precancerous lesions.

Jinhao Zeng, Ran Yan, Huafeng Pan, Fengming You, Tiantian Cai, Wei Liu, Chuan Zheng, Ziming Zhao, Daoyin Gong, Longhui Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Evidence-based complementary and alternative medicine : eCAM · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. RNA-Seq Analysis RevealsEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Weipiling ameliorates gastric precancerous lesions in Atp4aBMC complementary and alternative medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jinhao ZengChengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
Ran YanChengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
Huafeng PanGuangzhou University of Chinese Medicine, Guangzhou, 510405, China. gzphf@gzucm.edu.cn.
Fengming YouChengdu University of Traditional Chinese Medicine, Chengdu, 610075, China. yfmdoc@163.com.ORCID http://orcid.org/0000-0001-7900-4060
Tiantian CaiGuangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Wei LiuGuangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Chuan ZhengChengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
Ziming ZhaoGuangdong Provincial Institute of Chinese Medicine, Guangzhou, 510095, China.
Daoyin GongChengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
Longhui ChenGuangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China.
Yi ZhangChengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
Chengdu University of Traditional Chinese Medicine · CNGuangzhou University of Chinese Medicine · CNChinese Academy of Sciences · CN

Funding

National Natural Science Foundation of China 81473620National Natural Science Foundation of China 81673946National Natural Science Foundation of China 81774284Science and Technology Developmental Foundation of Affiliated Hospital of Chengdu University of TCM 2016-D-YY-34
6 · The paper itself

Abstract

backgroundAngiogenesis is a pathobiological hallmark of gastric cancer. However, rare studies focus on angiogenesis in gastric precancerous lesions (GPL). Weipixiao (WPX), a Chinese herbal preparation, is proved clinically effective in treating GPL. Here, we evaluated WPX's anti-angiogenic potential for GPL, and also investigated the possibility of its anti-angiogenic mechanisms.

methodsHPLC analysis was applied to screen the major chemical components of WPX. After modeling N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced GPL in male Sprague-Dawley rats, different doses of WPX were administrated orally for 10 weeks. Next, we performed histopathological examination using routine H&E staining and HID-AB-PAS staining. In parallel, we assessed angiogenesis revealed by microvessel density (MVD) using CD34 immunostaining, and subsequently observe microvessel ultrastructure in gastric mucosa under Transmission Electron Microscope. Finally, we detect expression of angiogenesis-associated markers VEGF and HIF-1α using immunohistochemistry. Moreover, mRNA expressions of ERK1, ERK2, Cylin D1 as well as HIF-1α in gastric mucosa were determined by quantitative real-time reverse transcription- polymerase chain reaction.

resultsWe observed the appearance of active angiogenesis in GPL rats, and demonstrated that WPX could reduce microvascular abnormalities and attenuate early angiogenesis in most of GPL specimens with a concomitant regression of most intestinal metaplasia (IM) and a portion of gastric epithelial dysplasia (GED). In parallel, WPX could suppress HIF-1α mRNA expression (P < 0.01) as well as protein expression (although without statistical significance), and could markedly inhibit VEGF protein expression in GPL rats. Mechanistically, WPX intervention, especially at low dose, caused a significant decrease in the ERK1 and Cylin D1 mRNA levels. However, WPX might probably have no regulatory effect on ERK2 amplification.

conclusionsWPX could attenuate early angiogenesis and temper microvascular abnormalities in GPL rats. This might be partly achieved by inhibiting on the angiogenesis-associated markers HIF-1α and VEGF, and on the ERK1/Cylin D1 aberrant activation.

Indexed as

Neovascularization, PathologicAngiogenesis InhibitorsAnimalsDrugs, Chinese HerbalGastric MucosaHypoxia-Inducible Factor 1, alpha SubunitMaleRatsRats, Sprague-DawleyStomachStomach NeoplasmsVascular Endothelial Growth Factor AAngiogenesis InhibitorsDrugs, Chinese HerbalHypoxia-Inducible Factor 1, alpha SubunitVascular Endothelial Growth Factor AweipixiaoERK signalingGastric precancerous lesionsHerbal medicineHIF-1αVEGFWeipixiao

Identifiers

PMID30200948
PMCPMC6131880
OpenAlexW2890476565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.